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MaA bidirectional relationship exists between atrial fibrillation (AF) and chronic renal disease. Patients with AF have a higher
incidence of renal dysfunction, and the latter predisposes to incident AF. The coexistence of both conditions results in a
higher risk for thromboembolic-related adverse events but a paradoxical increased hemorrhagic risk. Oral anticoagulants
(both vitamin K antagonists [VKAs] and non-VKA oral anticoagulants [NOACs]) have been demonstrated to be effective
in mild to moderate renal dysfunction. Patients with severe renal impairment were excluded from the non-VKA oral
anticoagulant trials, so limited data are available. In end-stage renal failure, the net clinical benefit of VKAs in dialysis-
dependent patients remains uncertain, although some evidence suggests that such patients may do well with high-
quality anticoagulation control. Risk stratification and careful follow-up of such patients are necessary to ensure a net
clinical benefit from thromboprophylaxis. (J Am Coll Cardiol 2016;68:1452–64) © 2016 by the American College of
Cardiology Foundation.C hronic kidney disease (CKD) is defined byKidney Disease Improving Global Outcomesas a reduction in renal function with
a reduction in glomerular filtration rate (GFR)
<60 ml/min/1.73 m2 for 3 months or longer or with
the presence of albuminuria (1,2). The scheme of
CKD stages 1 to 5 is conventionally classified on the
basis of GFR, ranging from CKD stage 1, which has
preserved renal function (GFR >90 ml/min) to CKD
stage 5, which has the worst renal function (GFR
<15 ml/min). CKD has potential for gradual progres-
sion to end-stage renal disease (ESRD), which
requires dialysis to correct the accompanying fluid
and electrolyte imbalance.
The increasing incidence and prevalence of CKD are
also associated with a parallel rise in incident atrial
fibrillation (AF) (3–6). The main reason for this epide-
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in the collective risk factors shared by both conditions,
such as diabetes mellitus and hypertension.
Unsurprisingly, CKD and AF are not independent
conditions, as several studies and national registries
have highlighted the increased incidence of AF
among those with worsening renal function (7–14).
Indeed, the incidence of AF development can be as
high as 12.1/1,000 patient-years in ESRD compared
with 5.0/1,000 patient-years in controls (15). Like-
wise, a new diagnosis of AF not only heralds the
progression of CKD but also hastens the development
of ESRD (16–18). AF also leads to the progression of
CKD, even among those with relatively “normal”
renal function, with no detectable proteinuria on
dipstick test at baseline (19). Thus, a bidirectional
relationship exists between these 2 conditions.s, Birmingham City Hospital, Birmingham, United
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
b.i.d. = twice daily
CKD = chronic kidney disease
ESRD = end-stage
renal disease
FDA = Food and Drug
Administration
NOAC = non-vitamin K
antagonist oral anticoagulant
TTR = time in therapeutic
range
VKA = vitamin K antagonist
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1453AF per se can result in increased risk of ischemic
stroke and systemic thromboembolism and indepen-
dently increased risk of cardiovascular death. How-
ever, the concurrent presence of both AF and CKD
further exacerbates the stroke and mortality risks,
with a 66% increase in relative risk of death (20–23).
Hence, the presence of both of these conditions re-
sults in an increase in the propensity for
thromboembolism-related adverse events (including
stroke, systemic thromboembolism, myocardial
infarction, and death) but a paradoxical increase in
hemorrhagic risk.
Stroke/thromboembolism and bleeding risks can be
assessed using clinical risk scores, such as the
CHA2DS2-VASc (congestive heart failure, hyperten-
sion, age $75 years, diabetes mellitus, prior stroke,
transient ischemic attack [TIA], or thromboembolism,
vascular disease [prior myocardial infarction, pe-
ripheral arterial disease or aortic plaque], age 65–74
years, sex category [female]) and HAS-BLED (hyper-
tension, abnormal renal/liver function, prior stroke,
bleeding history or predisposition, labile interna-
tional normalized ratio, elderly, drugs/alcohol)
scores, to enable risk stratification of patients
requiring thromboprophylaxis (24,25). Oral anticoag-
ulants (both vitamin K antagonists [VKAs] and non-
VKA oral anticoagulants [NOACs]) provide effective
thromboprophylaxis in patients with mild to moder-
ate renal dysfunction (creatinine clearance [CrCl] of
30 to 79 ml/min), in both clinical trials and observa-
tional studies (26,27). Patients with severe renal
impairment (CrCl <25 to 30 ml/min) were excluded
from the phase 3 randomized trials of NOACs, so
limited trial data are available.
Initially, this review discusses the pathophysio-
logical and clinical bases underlying the increased
risk of thromboembolism and hemorrhage among AF
patients with CKD. Second, we review the data for the
use of oral anticoagulants for stroke prevention in AF
across the spectrum of renal dysfunction.
SEARCH STRATEGY
A comprehensive search of published studies was
performed using electronic bibliographic databases
(i.e., PubMed, Medline, EMBASE, DARE, Cochrane
database), scanning reference lists from included
papers, and manual searching abstracts from national
and international cardiovascular meetings. Search
terms included: atrial fibrillation; chronic kidney
disease; renal failure; antithrombotic treatment;
vitamin K antagonist; dabigatran; rivaroxaban; apix-
aban; and edoxaban. Bibliographies of all selected
papers and reviews were reviewed for other relevantpapers. Finally, the supplements of major
journals were searched manually to identify
relevant abstracts that had not been pub-
lished as peer-reviewed papers.
PATHOPHYSIOLOGY AND
EPIDEMIOLOGY OF
THROMBOEMBOLISM IN CKD:
A BRIEF OVERVIEW
PATHOPHYSIOLOGICAL INSIGHTS. AF con-
fers a prothrombotic or hypercoagulable state
through numerous pathophysiological path-
ways, fulfilling Virchow’s triad for thrombo-
genesis, as shown by abnormalities in blood
flow, in the vessel wall, and in blood constituents
(28). The propensity of thrombus formation is further
enhanced by the relationship between CKD and
additional changes (29) in blood flow within the left
atrium (and left atrial appendage), endothelial dam-
age/dysfunction, or up-regulation of platelet and
coagulation factors (Table 1).
In relation to changes in blood flow, worsening GFR
in AF is associated with reduced left atrial appendage
emptying velocity and formation of dense sponta-
neous echocardiographic contrast, indicative of sig-
nificant blood stasis and increased thrombogenic risk
(30,31). Second, CKD-related endothelial damage/
dysfunction to the vessel wall maymanifest directly as
abnormal endothelial function (e.g., as assessed by
flow-mediated dilation) or increased pulse-wave ve-
locity (32–36), or indirectly, as elevated levels of
endothelin and von Willebrand factor (33,37). Endo-
thelial damage/dysfunction can also be reflected in
intima-media thickening (38), which is predictive of a
10-fold increase in cardiovascular mortality in patients
with ESRD (odds ratio: 10.20; 95% confidence interval
[CI]: 3.67 to 28.3; p < 0.0001) (39,40).
Third, increased thrombogenesis in CKD is also
related to an increase in platelet and coagulation
abnormalities (“abnormal blood constituents”)
through several pathways, for example, increased
procoagulant and inflammatory complexes (41–45),
up-regulation of the tissue factor pathway and its
interactions with platelets (46,47), reduction of
antithrombin III and plasminogen-activator inhibitor
(PAI)-1 levels (47,48), reduced von Willebrand factor
degradation (49), and increased platelet aggreg-
ability (50).
CKD per se is also associated with various other
factors contributing to an increased thromboembolic
risk, for example, activation of the renin-angiotensin-
aldosterone system (51), chronic inflammation (43),
aortic or vascular calcification, and dysfunction of
TABLE 1 Pathophysiology of Thromboembolism in CKD
First Author (Year) (Ref. #) Study Type N Population Findings
Blood stasis in left atrium and atrial appendage
Yagishita et al. (2010) (30) Observational 321 Patients with persistent atrial
fibrillation
GFR is an independent predictor of reduced left atrial
appendage emptying velocity and presence of left atrium
spontaneous echocardiographic contrast
Providência et al. (2013) (31) Observational 372 Patients with nonvalvular atrial
fibrillation
eGFR is positively associated with dense, spontaneous
echocardiographic contrast, and low flow velocities in the
left atrium
Damage to vessel wall and endothelial damage/dysfunction
Heintz et al. (1994) (37) Comparative 40 CKD and healthy controls CKD patients have higher endogenous levels of ET-1, plasma
cAMP, and enhanced ET-1-stimulated ADP-induced
platelet aggregation than healthy controls
Blacher et al. (1999) (32) Observational 241 ESRD patients Increased aortic PWV in ESRD predicts all-cause cardiovascular
mortality
Bolton et al. (2000) (33) Cross-sectional 67 23 HD patients, 16 NDD patients,
and 28 healthy controls
Reduced flow-mediated EDD in HD and NDD patients
compared to controls; increased vWF and adhesion
molecules in renal dysfunction
Yildiz et al. (2003) (34) Comparative 104 104 HD patients vs. 49 healthy
controls
Reduced flow-mediated EDD and EID in hemodialysis patients
compared to controls
Hrafnkelsdóttir et al. (2004) (137) Comparative 18 Nondiabetic, nonsmoking CKD
patients and age-matched
controls
Maximal release of active t-PA and capacity for active t-PA
release markedly impaired in CKD patients versus controls
Wang et al. (2005) (35) Observational 102 NDD CKD patients with various
GFR
Decreased GFR was independently associated with an
increased PWV
Carrero et al. (2012) (36) Observational 630 NDD CKD versus ESRD Prolactin levels increased along with reduced kidney function,
related to FMD, PWV, and increased risk of cardiovascular
events and mortality
Recio-Mayoral et al. (2011) (38) Comparative 141 76 CKD vs. 65 age- and sex-
matched controls
CKD patients had increased CRP levels, reduced FMD, and
increased IMT values compared to controls
Platelet and coagulation abnormalities
Shlipak et al. (2003) (41) Cross-sectional 5,888 Population-based cohort of age
>65 yrs
CRP, fibrinogen, IL-6, factor VII, factor VIII, plasmin-
antiplasmin complex, and D-dimer levels significantly
higher in CKD
Pecoits-Filho et al. (2003) (42) Observational 176 176 NDD patients Lower GFR associated with increased CRP, IL-6, hyaluronan,
and neopterin levels
Keller et al. (2008) (43) Cross-sectional 6,814 Population-based cohort 45-84 CRP, IL-6, TNF, TNF-aR1, intercellular adhesion molecule-1,
fibrinogen, and factor VIII levels are significantly higher in
CKD
Landray et al. (2004) (44) Comparative 522 334 CKD patients, 92 CAD
patients, 96 healthy controls
with no prior CV or renal
disease
CKD is associated with higher fibrinogen, plasma vWF, and
soluble P-selectin, but not CRP
Tanaka et al. (2009) (45) Observational 190 Patients not receiving oral
anticoagulant stratified by CrCl
Decreased GFR predicts for elevation of TAT and D-dimer in
patients with AF
Mercier et al. (2001) (46) Cross-sectional 150 50 ESRD patients, 50 NDD CKD
patients, and 50 healthy
controls
Reduced renal function associated with enhanced tissue factor
coagulation due to platelet, monocyte, and endothelial
injury
Costa et al. (2008) (48) Observational 50 50 ESRD patients vs. 25 healthy
controls
Higher levels of CRP, s-IL2R, IL-6, and D-dimer, and
significantly lower levels of PAI-1 in ESRD patients; the
t-PA/PAI-1 ratio was also significantly higher in ESRD
patients
Adams et al. (2008) (47) Comparative 102 66 CKD stage 4 and 5 patients
versus 36 healthy controls
Up-regulation of the tissue factor pathway, increased
prothrombin fragments 1 þ 2, and reduction in
antithrombin III in CKD compared with healthy controls
Shen et al. (2012) (49) Observational 104 104 NDD patients versus 32
healthy controls
Increased vWF-antigen level and decreased ADAMTS13 activity
in CKD
Yagmur et al. (2015) (50) Comparative 84 30 HD patients, 34 renal
transplant recipients, 20
healthy controls
Increased platelet hyperaggregability in CKD
ADAMTS13 ¼ a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; ADP ¼ adenosine diphosphate; AF ¼ atrial fibrillation; CAD ¼ coronary artery disease; cAMP ¼ cyclic
adenosine monophosphate; CKD ¼ chronic kidney disease; CrCl ¼ creatinine clearance; CRP ¼ C-reactive protein; CV ¼ cardiovascular; EDD ¼ endothelium-dependent dilation; eGFR ¼ estimated glomerular
filtration rate; EID ¼ endothelium-independent dilation; ESRD ¼ end-stage renal disease; ET ¼ endothelin; FMD ¼ flow-mediated dilation; GFR ¼ glomerular filtration rate; HD ¼ hemodialysis;
IL ¼ interleukin; IMT ¼ intima-media thickness; MDRD ¼ Modification of Diet in Renal Disease; NDD ¼ nondialysis dependent; PAI ¼ plasminogen activator inhibitor; PWV ¼ pulse wave velocity; s-IL2R ¼
serum interleukin-2 receptor; TAT¼ thrombin-antithrombin complex; TNF ¼ tumor necrosis factor; TNF-aR1 ¼ tumor necrosis factor-a soluble receptor 1; t-PA, tissue-type plasminogen activator; vWF ¼ von
Willebrand factor.
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TABLE 2 Epidemiological Insight Into Stroke Risk in Patients With AF and CKD
First Author (Year) (Ref. #) Study Type N Findings
Go et al. (2009) (55) Retrospective 10,908 AF with CKD Compared with GFR $60 ml/min/1.73 m2:
eGFR: 45–59 ml/min; RR: 1.16 (95% CI: 0.95–1.40)
eGFR <45 ml/min; RR: 1.39 (95% CI: 1.13–1.71)
(p ¼ 0.0082 for trend).
Friberg et al. (2012) (138) Retrospective 182,678 AF patients
(8,113 with CKD)
CKD stage 1 and below: multivariate HR: 1.11
(95% CI: 0.99–1.25)
Olesen et al. (2012) (56) Retrospective 132,372 AF patients
(3,587 with NDD CKD; 901
with ESRD)
Compared with GFR $90 ml/min/1.73 m2:
NDD CKD HR: 1.49 (95% CI: 1.38–1.59)
ESRD, HR: 1.83 (95% CI: 1.57–2.14)
Guo et al. (2013) (18) Prospective 617 AF patients Risk of stroke or death: HR: 2.90 (95% CI: 1.88–4.48)
Risk of stroke in 6 months:
Absolute decrease in eGFR $25 ml/min/1.73 m2: HR:
2.77 (95% CI: 1.26–6.09)
Relative decrease in eGFR $25%: HR: 2.57
(95% CI: 1.14–5.80)
Roldán et al. (2013) (61) Prospective 978 AF patients on VKA Every decrease in eGFR of 30 ml/min/1.73 m2:
HR: 1.42 (95% CI: 1.11–1.83)
Bonde et al. (2014) (57) Retrospective 154,254 nonvalvular AF patients
(148,598 with NRD; 4,519 with
NDD; 1,142 receiving RRT)
Compared with GFR $60 ml/min/1.73 m2:
NDD CKD, HR: 1.32 (95% CI: 1.23–1.42)
RRT, HR: 2.01 (95% CI: 1.74–2.33)
Chao et al. (2014) (139) Retrospective 10,999 AF patients with ESRD
in Taiwan
11.7% of patients experienced ischemic stroke
Absolute stroke and thromboembolism event rate:
6.9/100 patient-years
Banerjee et al. (2014) (140) Prospective 8,962 AF patients
(2,982 with CKD)
Compared with GFR $60 ml/min/1.73 m2:
eGFR 30–59 ml/min HR: 1.53 (95% CI: 1.10–2.12)
eGFR <30 ml/min HR: 1.78 (95% CI: 0.99–3.19)
CI ¼ confidence interval; HR ¼ hazard ratio; NDD ¼ nondialysis-dependent; RR ¼ relative risk; RRT ¼ renal replacement therapy; other abbreviations as in Table 1.
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1455calcium-phosphate mineral metabolism, which has
been related to renal dysfunction (52–54).
EPIDEMIOLOGICAL INSIGHTS. An increase in stroke
risk with progressive severe CKD among AF patients
is evident from several large observational studies
(Table 2).
The ATRIA (AnTicoagulation and Risk factors In
Atrial fibrillation) study (55) found that the presence
of proteinuria increased risk of thromboembolism in
AF by 54%. Progressive worsening of GFR was also
associated with increased risk of stroke, where a
GFR <45 ml/min/1.73 m2 conferred an increased risk
of 39% compared with a GFR >60 ml/min/1.73 m2.
In separate analyses from the Danish nationwide
cohort study, Olesen et al. (56) and Bonde et al. (57)
reported that patients with concurrent AF and CKD
experienced significantly higher rates of stroke,
thromboembolism, hemorrhage, and death than
those without renal disease. Those with ESRD
requiring renal replacement therapy fared the worst:
such patients were twice as likely to experience
stroke and thromboembolism (57) than those without
renal dysfunction (15). Similar relationships, for
example, between an increased incidence of AF with
progressive renal failure and a resultant increase in
adverse events, have been shown in the Swedish
national cohort study, as well as in various studies
from Asian countries (15,58–60).Among those with CKD (GFR <60 ml/min/1.73 m2),
the sequential deterioration of renal function over
time is equally pertinent, as an absolute reduction in
estimated GFR (eGFR)$25 ml/min/1.73 m2 or a relative
reduction of eGFR$25% effectivelymore than doubles
the risk of ischemic stroke compared to those with
relatively “stable” renal function over a 6-month
period (18). Even among AF patients treated with
effective anticoagulation, every 30 ml/min/1.73 m2
reduction in eGFR confers a markedly increased risk of
thrombotic or vascular event (hazard ratio [HR]: 1.42;
95% confidence interval [CI]: 1.11 to 1.83; p ¼ 0.006)
(61). Worsening renal clearance is not only an inde-
pendent predictor of stroke mortality but is associated
with a worse adverse outcome after stroke (62,63).
HEMORRHAGIC TENDENCY IN CKD
Although it significantly increases the risk of throm-
boembolism and ischemic stroke in AF, CKD also
paradoxically results in an increased risk of hemor-
rhagic events.
Evidence from both the Rotterdam study and the
Japanese CIRCS (Circulatory Risk in Communities
Study) trial shows that the presence of reduced renal
function (GFR <60 ml/min/1.73 m2) results in a more
than 4-fold increased risk of hemorrhagic stroke in
men and a 7-fold increased risk in women (64,65).
CKD patients undergoing chronic dialysis had a
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>10-fold higher (66). Worsening renal function and
associated vascular dysfunction may result in an
increased tendency for formation of magnetic reso-
nance imaging-defined cerebral microbleeds, which
have the potential of contributing to subsequent
intracerebral hemorrhage (67).
The risk of gastrointestinal bleeding is also
increased, whether peptic ulcer-related, nonpeptic
ulcer-related, or nonvariceal gastrointestinal bleeds;
of note, the recurrence, frequency, and severity of
such episodes are all closely linked to impairment of
renal function (68–70). Similar to intracranial hem-
orrhage, both forms of renal replacement therapy
(peritoneal dialysis and hemodialysis) are associated
with an increased risk of gastrointestinal hemorrhage,
conferring hazard ratios of 3.71 (95% CI: 2.00 to 6.87;
p < 0.001) and 11.96 (95% CI: 7.04 to 20.31; p < 0.001),
respectively (71).
The pathophysiological causes of the increased risk
of hemorrhagic events are clearly multifactorial. They
can be a direct result of uremia-related platelet
dysfunction or impaired platelet adhesion and ag-
gregation; impaired platelet glycoprotein IIb or IIIa
receptor activation and subsequent binding to
glycoprotein; altered von Willebrand factor; and ni-
tric oxide metabolism (72–74). Extrinsically, the pro-
pensity to bleed can be the result of concurrent use of
antiplatelet agents or nonsteroidal anti-inflammatory
drugs. Moreover, patients with ESRD would be sub-
ject to frequent invasive diagnostic and invasive
strategies, such as central venous access and hemo-
dialysis (plus subsequent frequent heparin exposure),
which could also increase their bleeding risk.
STROKE AND BLEEDING RISK
STRATIFICATION IN AF WITH CKD
In the general AF population, the risk of stroke is
5-fold increased overall, according to the presence or
absence of various stroke risk factors. The more
common risk factors have been used to formulate
stroke risk stratification schemes to help decision
making about whether an oral anticoagulant (OAC)
should be recommended or not for stroke prevention.
However, all risks that are scored on the basis of
clinical factors have modest predictive value for
identifying “high-risk” patients who sustain events.
Current AF guidelines have adopted the use of the
CHA2DS2-VASc score, given that it can reliably iden-
tify truly “low-risk” patients (i.e., CHA2DS2-VASc
score of 0 in men, 1 in women) who do not need
antithrombotic therapy (75,76). Subsequent to this
step, effective stroke prevention can be offered tothose AF patients with $1 stroke risk factors. Effec-
tive stroke prevention means OACs, whether as well-
controlled VKA therapy or one of the NOACs.
Despite being a contributor to an increased throm-
boembolic risk, moderate-severe renal impairment is
not included in the CHA2DS2-VASc score, as attempts
to incorporate renal impairment into the stroke
risk stratification scheme have not shown an inde-
pendent additive predictive value for renal impair-
ment over the CHA2DS2-VASc score components,
probably because CKD is strongly associated with the
various single-risk factor components of the CHA2DS2-
VASc score (i.e., heart failure, hypertension, and dia-
betes mellitus, among others).
One study advocating the addition of renal
impairment for stroke risk stratification proposed the
R2CHADS2 score (the additional R was for impaired
renal function and given 2 points). In its initial deri-
vation study from a highly selected anticoagulated
clinical trial population with exclusion of those with
severe CKD, the R2CHADS2 score modestly improved
the c-index (a statistical measure of the score’s pre-
dictive value for high-risk patients who sustain
events) of the CHADS2 and CHA2DS2-VASc scores (77).
However, the statistically significant modest
improvement in predictive value of R2CHADS2 for
thromboembolism has not been replicated in a small-
sized ESRD cohort (78) and other similar studies
(79,80) or in an AF cohort undergoing invasive cath-
eter ablation of AF (81). In other large “real-world”
non-anticoagulated AF cohorts, renal dysfunction
(whether with 1 or 2 points, as with R2CHADS2) did
not independently improve the predictive value of
the CHADS2 and CHA2DS2-VASc scores (82,83).
For hemorrhagic risk stratification in AF, guide-
lines currently recommend the use of the HAS-BLED
score for assessing bleeding risk. A high HAS-BLED
score should not lead to withholding of oral anti-
coagulation therapy, but a high HAS-BLED score
among those with CKD should flag the patients
potentially at risk of bleeding for more careful review
or follow-up and the correction of modifiable risk
factors, such as uncontrolled hypertension (the H of
the HAS-BLED), labile international normalized ra-
tios, alcohol excess, or concomitant use of nonste-
roidal anti-inflammatory drugs and aspirin.
For those patients with previous gastrointestinal
hemorrhage, the resumption of oral anticoagulant
treatment has been associated with a significant
reduction of mortality and thromboembolic events
(84,85). Similar findings have also been seen in an
ESRD cohort of patients with an increased risk of
recurrence of gastrointestinal bleed upon restarting
warfarin (86).
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The approach to clinical management of AF patients
with CKD has recently been comprehensively
addressed by a position paper from the EuropeanHeart
Rhythm Association, endorsed by the Heart Rhythm
Society and the Asia Pacific Heart Rhythm Society (87).
In general, the management of AF is patient-centered
and symptom-directed when it comes to deciding on
rate or rhythm control strategies (88,89); however,
limited data are available on the differential
management of AF in patients with CKD. Drug phar-
macokinetics of antiarrhythmic agents and some an-
ticoagulants may be influenced by CKD, and dosages
may need adjustment due to the prolonged half-lives
of various drugs and reduced clearance (87). Some
drugs can even be removed by dialysis.
One recent study in European countries reported
that patients with mild to moderate CKD were more
likely treated with a rhythm control approach,
whereas patients with severe CKD were more likely
treated with a rate control approach (90). Also, AF
ablation procedures were infrequently performed in
patients with advanced CKD (90).
This approach seems justified, given the lack of
proven long-term efficacy of ablation procedures in
patients with CKD. In fact, one meta-analysis of
observational studies in this clinical setting found
CKD to be associated with a higher AF recurrence risk
(91). Similar data have been reported for AF patients
undergoing chronic dialysis (92). Indeed, worsening
renal function during follow-up after catheter abla-
tion seems to be associated with the highest risk of AF
recurrence (93). In patients with new-onset AF after
myocardial infarction, there were no significant dif-
ferences in short- and long-term mortality rates be-
tween rate and rhythm control strategies in patients
with CKD (94).
ORAL ANTICOAGULATION IN CKD:
USING VITAMIN K ANTAGONISTS
Although oral anticoagulation is the mainstay of
treatment for the prevention of ischemic stroke and
thromboembolism in patients with AF, less evidence
exists for those with significant renal impairment,
given that such patients were excluded from the
randomized trials. Hence, the prescription of oral
anticoagulants (essentially VKAs, e.g., warfarin)
among those with significant renal impairment varies
from as low as 2% in Germany to as high as 37% in
Canada (58). This heterogeneity in clinical practice
reflects the uncertainty about the risks and benefits of
anticoagulation use within this patient group.For AF patients with concomitant ESRD requiring
renal replacement therapy, conflicting findings exist
from observational studies relating to the efficacy and
safety associated with use of VKAs (Table 3).
Of the 17 studies reviewed, only the study by
Abbott et al. (95) showed a clear mortality benefit,
and Olesen et al. (96), Bonde et al. (57), Genovesi et al.
(97), Chan et al. (98), and Findlay et al. (99) found a
reduction in stroke or thromboembolism event rates.
Other studies involving ESRD patients and use of VKA
have demonstrated either equivocal results (100–102)
or even potential harm from VKA use (100,103–110).
Several large studies (104,105,108) have demon-
strated that AF patients who are receiving hemodi-
alysis and taking warfarin experienced a more
than 2-fold increase in the risk of ischemic stroke
compared to non-VKA users. Elderly patients
(>75 years of age) appear to be particularly at risk
compared with those below 65 years of age (105). At
the same time, those taking VKA while receiving he-
modialysis may have a higher risk of hemorrhagic
stroke than of thromboembolic events (107).
Possible explanations for the lack of efficacy of
VKA in protection against stroke and thromboembo-
lism and potential increase in stroke risk may be the
poor quality of anticoagulation control, as reflected
by a low time in therapeutic range (TTR) for patients
receiving renal replacement therapy. Indeed, the
Swedish AF cohort study suggests that the improved
TTR is associated with lower risk of thromboembo-
lism and hemorrhage (58).
Another possible explanation may potentially be
dependent on the modality used in renal replace-
ment therapy. A recent Hong Kong AF cohort sug-
gested that ESRD patients receiving peritoneal
dialysis had a thrombotic risk similar to that of their
nonperitoneal dialysis counterparts. Importantly,
warfarin use in this particular patient group not
only provided protection against ischemic stroke
(HR: 0.16; 95% CI: 0.04 to 0.66; p < 0.01 compared
with aspirin; and HR: 0.19; 95% CI: 0.06 to 0.65;
p < 0.01 compared with no antithrombotic therapy)
but there was no increased risk of intracranial
hemorrhage (with only 2 events occurring, 1 in the
aspirin group and 1 in the no-antithrombotic ther-
apy group) (98).
Among non–dialysis-dependent CKD patients with
AF, there are more robust data favoring the use of
dose-adjusted VKA in AF (Table 4). In all 5 studies and 1
meta-analysis reviewed, dose-adjusted warfarin pro-
vided better protection against ischemic stroke and
systemic embolism than nonuse (56,57,109,111–113).
The efficacy of warfarin in reducing thromboembolism
must be balanced against a small but significant
TABLE 3 VKA Use and Stroke Rates in ESRD
First Author (Year) (Ref. #) Study Type Number (% With AF) Findings
Wiesholzer et al. (2001) (103) Retrospective observational 430 (14.3%) Stroke rate/100 patient-years:
AF with VKA: 4.46
AF without VKA: 1.0
Abbott et al. (2003) (95) Retrospective observational 3,374 (1.25%) 3-year survival rate:
AF with VKA: 70%
AF without VKA: 55%
Chan et al. (2009) (104) Retrospective observational 48,825 (3.42%) 90-day HR:
AF with VKA: 1.93 (95% CI: 1.29–2.90)*
Wizemann et al. (2010) (105) Observational (DOPPS) 17,513 (12.5%) Stroke rate in subjects >75 yrs of age:
Warfarin user: 2.17 (95% CI: 1.04–4.53)
Phelan et al. (2011) (106) Retrospective 845 requiring dialysis
(141 on warfarin)
Stroke rate/100 patient-years:
VKA user: 1.7 vs. non-VKA user: 0.7 (p ¼ 0.636)
Major hemorrhage rate/100 patient-years:
VKA user: 10.8 vs. non-VKA user: 8.0 (p ¼ 0.593)
Winkelmayer et al. (2011) (107) Retrospective observational 2,313 ESRD patients with new AF HR for ischemic stroke: VKA user 0.92 (95% CI: 0.61–1.37)
HR for hemorrhagic stroke: VKA user 2.38 (95% CI: 1.15–4.96)
Olesen et al. (2012) (56) Subgroup analysis 901 patients with AF requiring
dialysis
HR compared with no antithrombotic agent, dialysis-
dependent patients:
VKA: 0.44 (95% CI: 0.69–1.01)
Knoll et al. (2012) (100) Prospective 235 patients on dialysis
(19.6% on VKA)
No stroke or bleed experienced
HR for mortality in VKA user: 0.80 (95% CI: 0.28–2.29)
Sood et al. (2013) (108) Observational
(DOPPS)
41,844 (9.71%) Stroke rate/100 patient-years:
VKA: 3.3
No VKA or antiplatelet: 2.1†
Bonde et al. (2014) (57) Retrospective 154,254 nonvalvular AF patients
(1,142 on RRT and 260 receiving
VKA)
Stroke and thromboembolic risk in non-VKA users:
HR: 1.82 (95% CI: 1.58–2.12)‡
Shah et al. (2014) (109) Retrospective 1,626 patients with AF on RRT
(756 VKA users)
HR for ischemic stroke comparing VKA vs. non-VKA users:
1.14 (95% CI: 0.78–1.67)
HR for bleeding: 1.44 (95% CI: 1.13–1.85)
Chen et al. (2014) (102) Retrospective 500 with AF and ESRD
(250 receiving VKA)
Compared with control group (no VKA or antiplatelet agent):
HR for ischemic stroke: 1.017 (95% CI: 0.673–1.537)
Wakasugi et al.
(2014) (110)
Prospective 60 Japanese patients with AF
requiring dialysis (28 VKA
users)
Comparing VKA vs. non-VKA users
HR for ischemic stroke: 3.36 (95% CI: 0.67–16.66)
Chan et al. (2015) (98) Retrospective 271 patients with AF on peritoneal
dialysis (70 on VKA)
Comparing VKA vs. aspirin users:
HR for ischemic stroke: 0.16 (95% CI: 0.04–0.66)
Comparing VKA vs. nonusers of antithrombotic agents:
HR for ischemic stroke: 0.19 (95% CI: 0.06–0.65)
Findlay et al. (2015) (99) Retrospective 1.382 patients with ESRD, of
whom 293 with AF (118 on
VKA; 175 without VKA)
Stroke rate:
AF with VKA: 11.4%
AF without VKA: 14.4%
Genovesi et al. (2015) (97) Prospective 290 patients with AF requiring
dialysis (134 on VKA at
recruitment)
Comparing VKA vs. non-VKA users:
HR for stroke/thromboembolic events: 0.12
(95% CI: 0.00–3.59)
Shen et al. (2015) (101) Retrospective 12,284 patients on RRT
(1,383 started on VKA)
Comparing VKA vs. non-VKA users:
HR for ischemic stroke: 0.68 (95% CI: 0.47–0.99)
HR for mortality: 0.84 (95% CI: 0.73–0.97)
*AF with VKA covariate adjusted model: adjusted for CHADS2 (congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke, transient ischemic attack [TIA], or thromboembolism)
score, sex, race, Charlson comorbidity index, entry date, body mass index, facility standardized mortality ratio, cardiovascular drugs, dialysis adequacy, baseline laboratory values, heparin dosage, and heparin
regimes. †VKA users include patients with AF, thromboembolic disease, or central vascular catheter. ‡Adjusted for aspirin treatment and all risk factors included in CHA2DS2-VASc (congestive heart failure,
hypertension, age $75 years, diabetes mellitus, prior stroke, transient ischemic attack [TIA], or thromboembolism, vascular disease [prior myocardial infarction, peripheral arterial disease or aortic plaque],
age 65–74 years, sex category [female]) score.
DOPPS ¼ Dialysis Outcomes and Practice Pattern Study; VKA ¼ vitamin K antagonist; other abbreviations as in Tables 1 and 2.
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with an even higher event rate if there is concurrent
antiplatelet use (56,109). Therefore, VKAs can be
beneficial in non–dialysis-dependent CKD patients
with AF, but the propensity for harm due to VKAs in
ESRD has yet to be fully defined, especially in a
patient taking hemodialysis therapy. Some evidence
suggests that such ESRD patients may do well withhigh-quality anticoagulation control. One recent
ancillary analysis from a clinical trial cohort found
that good-quality anticoagulation control (TTR >70%)
was an independent predictor of lower risks of
stroke, death, and major bleeding (114). Risk stratifi-
cation and careful follow-up of such patients are
necessary to ensure a positive net clinical benefit
from thromboprophylaxis.
TABLE 4 VKA Use and Stroke/Thromboembolic Event Rate in Nondialysis-Dependent CKD Patients
First Author (Year) (Ref. #) Study Type Number Findings
Lai et al. (2009) (111) Observational 307 % Stroke event rate/yr:
Dose-adjusted warfarin (INR target: 2–3): 3.48
No VKA: 13.57
Hart et al. (2011) (112) Post hoc analysis 516 % Stroke/embolic event rate/yr:
Dose-adjusted warfarin: 1.45
Dose-adjusted warfarin plus aspirin: 7.05
Olesen et al. (2012) (96) Subgroup analysis 3,587 HR of stroke compared with no antithrombotic NDD CKD:
Warfarin only: 0.84 (95% CI: 0.69–1.01)
Warfarin þ aspirin: 0.76 (95% CI: 0.56–1.03)
Aspirin only: 1.25 (95% CI: 1.07–1.47)
Bonde et al. (2014) (57) Retrospective 154,254 nonvalvular AF patients
(4,519 on NES CKD, 1,130 on VKA)
Stroke and thromboembolic risk in non-VKA users:
HR: 1.31 (95% CI: 1.22–1.41)*
Shah et al. (2014) (109) Retrospective 204,210 NES patients with AF
(103,652 on VKA)
Stroke risk with warfarin use in nondialysis patients:
HR: 0.87 (95% CI: 0.85–0.90)
Bleeding risk in nondialysis patients:
HR: 1.19 (95% CI: 1.13–1.85)
Providência et al. (2014) (113) Meta-analysis 19 studies, 379,506 patients with
CKD and AF
Stroke and thromboembolic risk in non-NES VKA users:
HR: 0.39 (95% CI: 0.18–0.86)
*Adjusted for aspirin treatment and all risk factors included in the CHA2DS2-VASc score.
INR ¼ international normalized ratio; NES ¼ non–end-stage; other abbreviations as in Tables 1 and 3.
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1459WHAT ARE THE POSSIBLE PATHOPHYSIOLOGICAL
MECHANISMS? Apart from the abnormalities of
Virchow’s triad discussed previously, murine and
human studies have demonstrated that VKA contrib-
utes to vascular calcification through inactivation of
the matrix protein Gla (115,116). Increased vascular
calcification, either as a direct result of development
of ESRD or due to concurrent VKA usage, may
potentially increase the likelihood of development of
noncardioembolic stroke, which will not be remedied
by VKA use. Moreover, VKA administration has been
implicated in development of calciphylaxis, a painful
and lethal complication among patients with ESRD, as
cutaneous arteries and arterioles undergo calcifica-
tion and occlusion (117,118).
ORAL ANTICOAGULATION IN CKD:
USING NON-VKA ORAL ANTICOAGULANTS
When NOACs were introduced, namely the direct
thrombin inhibitor (dabigatran) and factor Xa in-
hibitors (rivaroxaban, apixaban, and edoxaban), they
were considered viable alternatives for patients with
mild to moderate CKD requiring an oral anticoagulant
for thromboprophylaxis.
All 4 NOACs demonstrated noninferiority or even
superiority in stroke prevention and noninferiority
(or, in some cases, superiority) in bleeding profile
compared with warfarin (119–123). Subgroup ana-
lyses of patients with renal dysfunction showed that
both of the dabigatran dosages are effective and
safe, regardless of renal function (124), whereas a
reduction in rivaroxaban dosage to 15 mg once perday in patients with moderate CKD provides efficacy
and safety comparable to that of warfarin (125).
Among patients with moderately reduced renal
function (GFR as low as 30 ml/min), the apixaban
and edoxaban subgroups of the ARISTOTLE (Apix-
aban for Reduction in Stroke and Other Thrombo-
embolic Events in Atrial Fibrillation) and ENGAGE
AF-TIMI 48 (Effective Anticoagulation with Factor
Xa Next Generation in Atrial Fibrillation-Thrombol-
ysis In Myocardial Infarction 48) trials showed a
reduced bleeding risk compared with that of
warfarin (126,127). Additional benefits include
medication delivery in fixed doses that do not
require monitoring and that have a lower propensity
for interaction with food or other medications
(128,129).
Nonetheless, as all NOACs have a degree of renal
excretion (varying from 25% in apixaban to 80% in
dabigatran), in their respective trials, participants
with severe renal dysfunction or ESRD were
excluded. Therefore, the European guidelines
recommend that the NOACs are best not used where
severe renal impairment (GFR <25 to 30 ml/min) is
present (75,130). Among patients with moderately
impaired renal function (GFR 30 to 49 ml/min), dose
alteration according to manufacturer’s recommenda-
tions is advised. The Cockcroft-Gault method should
be used (rather than the Modification of Diet in Renal
Disease [MDRD] or Chronic Kidney Disease Epidemi-
ology equations) for the assessment of renal function,
as this formula was used during various randomized
trials of NOACs and does not result in overestimation
of renal function in elderly patients or those with
CENTRAL ILLUSTRATION Proposed Algorithm for Oral Anticoagulant Choices in Patients With Atrial Fibrillation
and Chronic Kidney Disease
Address bleeding risk factors, frequent follow up, and closely monitor renal function in NOAC users
and chronic kidney disease
Estimate creatinine clearance (CrCl ) to determine appropriate oral anticoagulant (OAC)
Determine stroke risk (CHA2DS2-VASc Score)
Determine bleeding risk (HAS-BLED Score)
CrCl  < 15 ml/min
or ESRD on RRT
Vitamin K
antagonist
OAC options: CrCl  15–29 ml/min CrCl  30–49 ml/min
Apixaban 5 mg, b.i.d.* 2.5 mg, b.i.d.
Dabigatran 75 mg, b.i.d.
Edoxaban 
Rivaroxaban 15 mg, o.d.
30 mg, o.d.
5 mg, b.i.d.†
150 or 110 mg, b.i.d.§‡
15 mg, o.d.
30 mg, o.d.
5 mg, b.i.d.†
150 mg, b.i.d.||
60 mg, o.d.¶
20 mg, o.d.
When time in
therapeutic
range >70%
When time in
therapeutic
range >70%
When time in
therapeutic
range >70%
When time in
therapeutic
range >70%
Lau, Y.C. et al. J Am Coll Cardiol. 2016;68(13):1452–64.
We provide a suggested algorithm, set according to current evidence and guidelines, for the decision-making process in prescribing oral anticoagulant therapy in
patients with various degrees of renal function impairment. Careful evaluation of clinical factors is needed and is pivotal at every step of the process to correctly identify
the best option for every patient. *Only approved in the United States. †Use 2.5 mg b.i.d. if 2 of 3 of the following criteria are present: age >80 years old, weight <60
kg, serum creatinine >133 mmol/l. ‡Dabigatran 75 mg b.i.d. only licensed in the United States for CrCl 15-29 ml/min and not in the rest of the world; dabigatran 110 mg
b.i.d. not available in the United States. §Must be balanced relative to bleeding risk, age, and drug interactions; the 110-mg dose is not available in the United States.
kUnless the patient is elderly or has high bleeding risk or is taking p-glycoprotein inhibitors, where dabigatran, 110 mg twice daily is preferred, except in the United
States, where the 110-mg dose is not available. ¶In the United States only, caution is advised by the FDA, where CrCl is >95 ml/min. b.i.d. ¼ twice a day; CHA2DS2-
VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke, transient ischemic attack [TIA], or thromboembolism, vascular disease
[prior myocardial infarction, peripheral arterial disease or aortic plaque], age 65–74 years, sex category [female]; CrCl ¼ creatinine clearance; ESRD ¼ end-stage renal
disease; HAS-BLED ¼ hypertension, abnormal renal/liver function, prior stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/
alcohol; NOAC ¼ non-vitamin K antagonist oral anticoagulant; OAC ¼ oral anticoagulant; o.d. ¼ once daily; RRT ¼ renal replacement therapy.
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1460lower GFR, hence, providing better dose adjustment
in this patient group (29,131).
For patients in the United States, the Food and
Drug Administration (FDA) has approved dabigatran,
75 mg twice a day (b.i.d.); rivaroxaban, 15 mg once
daily; and apixaban, 2.5 mg b.i.d., for patients with a
CrCl of 15 to 29 ml/min. These dosages are not
approved on the basis of clinical trial outcome databut on pharmacological modeling data. Using phar-
macokinetic findings in patients who received he-
modialysis, the FDA has also approved the use of
apixaban, 5 mg b.i.d. (i.e., no dose adjustment), in AF
patients receiving chronic, stable hemodialysis treat-
ment (132). The FDA also raised concerns about the
use of edoxaban in AF patients with CrCl >95 ml/min,
but differences in stroke/thromboembolism, all-cause
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1461mortality, and cardiovascular mortality in relation to
CrCl renal subgroups were not statistically significant
in a comparison between edoxaban-treated and
warfarin-treated subgroups (133). The prescribing
label for edoxaban in Europe and elsewhere does
not have the FDA caution/restriction for use in AF
patients with CrCl >95 ml/min.
A recent meta-analysis has demonstrated the
relative safety and efficacy of all 4 NOAC agents over
that of warfarin across various degrees of renal
impairment (26). Although there is currently no head-
to-head clinical trial comparing one NOAC with
another, the same analysis also revealed that in
“moderate renal dysfunction” (CrCl 25 to 49 ml/min),
apixaban possessed a relatively better safety profile
while retaining similar power of efficacy in protection
against thromboembolic events (26). In those with
“mild renal dysfunction” (CrCl 50 to 79 ml/min),
dabigatran, 110 mg, and apixaban, rivaroxaban, and
edoxaban, 30 mg, appear broadly comparable (26).
CONCLUSIONS AND FUTURE PERSPECTIVES
Renal dysfunction and AF commonly coexist, and the
concurrent existence of both conditions results in a
paradoxical increase in both thromboembolic and
hemorrhagic risks. Several pathophysiological factors
have been demonstrated to induce a prothrombotic
state while increasing bleeding risk in such patients.
The thromboembolic and hemorrhagic risks are
particularly high among dialysis-dependent patients
with ESRD. However, at this juncture, data support-
ing the long-term use of VKA for thromboprophylaxis
in AF remain limited. Any potential benefit conferred
by VKA appears to be outweighed by a dispropor-
tionate increase in bleeding risk (and thrombotic
events). One specific NOAC (apixaban) has recentlybeen licensed for use in individuals undergoing he-
modialysis on the basis of limited pharmacokinetic
studies only. To the best of our knowledge, no spe-
cific outcome studies have been designed to explore
the comparative efficacy and safety of the different
OAC treatments in patients with severe CKD. Large
observational cohort studies with various NOACs and
well-managed VKA therapy (with TTR >70%) may
offer some comparative efficacy and safety data.
Conversely, the use of various oral anticoagulants
(whether VKAs or NOACs) among AF patients with
mild CKD has been shown to reduce morbidity and
mortality from stroke and systemic thromboembo-
lism. Even in moderately impaired renal function
(CrCl 30 to 49 ml/min) apixaban and edoxaban appear
to have a good safety profile (Central Illustration).
The key would be careful patient selection through
the use of risk stratification scores (e.g., using
CHA2DS2-VASc and HAS-BLED scores). Upon initia-
tion of oral anticoagulation, we should ensure that
steps are taken to reduce bleeding risk (e.g., aiming
for a high TTR, namely >70%) (134), plus regular
monitoring of renal function if a NOAC is chosen, to
allow for dose alteration as needed. Patients with
CKD and AF are prone to experience fluctuations of
renal function due to acute illness (135); thus, making
timely dose alterations is vital to preventing adverse
events (136). As a result of an increasingly elderly
population, the necessity of managing AF with con-
current CKD will increase rather than decrease in the
near future.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Gregory Y.H. Lip, University of Birmingham Institute
of Cardiovascular Sciences, City Hospital, Dudley
Road, Birmingham B18 7QH, United Kingdom. E-mail:
g.y.h.lip@bham.ac.uk.RE F E RENCE S1. Levey AS, Eckardt KU, Tsukamoto Y, et al.
Definition and classification of chronic kidney dis-
ease: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int
2005;67:2089–100.
2. Kidney Disease: Improving Global Outcomes
(KDIGO) CKD Work Group. KDIGO 2012 clinical
practice guideline for the evaluation and man-
agement of chronic kidney disease. Kidney Int
Suppl 2013;3:1–150.
3. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic
kidney disease: global dimension and perspec-
tives. Lancet 2013;382:260–72.
4. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic
kidney disease awareness, prevalence, and trends
among U.S. adults, 1999 to 2000. J Am Soc
Nephrol 2005;16:180–8.5. Heeringa J, van der Kuip DA, Hofman A, et al.
Prevalence, incidence and lifetime risk of atrial
fibrillation: the Rotterdam study. Eur Heart J
2006;27:949–53.
6. Alonso A, Bengtson LG. A rising tide: the global
epidemic of atrial fibrillation. Circulation 2014;
129:829–30.
7. Tsagalis G, Bakirtzi N, Manios E, et al. Atrial
fibrillation in chronic hemodialysis patients: prev-
alence, types, predictors, and treatment practices
in Greece. Artif Organs 2011;35:916–22.
8. Soliman EZ, Prineas RJ, Go AS, et al.,
Chronic Renal Insufficiency Cohort (CRIC) Study
Group. Chronic kidney disease and prevalent
atrial fibrillation: the Chronic Renal Insuffi-
ciency Cohort (CRIC). Am Heart J 2010;159:
1102–7.9. Alonso A, Lopez FL, Matsushita K, et al. Chronic
kidney disease is associated with the incidence of
atrial fibrillation: the Atherosclerosis Risk in
Communities (ARIC) study. Circulation 2011;123:
2946–53.
10. Ohyama Y, Imai M, Kurabayashi M. Estimated
glomerular filtration rate and proteinuria are
separately and independently associated with the
prevalence of atrial fibrillation in general popula-
tion. PloS One 2013;8:e79717.
11. Suzuki S, Sagara K, Otsuka T, et al. Estimated
glomerular filtration rate and proteinuria are
associated with persistent form of atrial fibrilla-
tion: analysis in Japanese patients. J Cardiol 2013;
61:53–7.
12. Horio T, Iwashima Y, Kamide K, et al. Chronic
kidney disease as an independent risk factor for
Lau et al. J A C C V O L . 6 8 , N O . 1 3 , 2 0 1 6
AF, CKD, and Thromboembolic Risk S E P T E M B E R 2 7 , 2 0 1 6 : 1 4 5 2 – 6 4
1462new-onset atrial fibrillation in hypertensive pa-
tients. J Hypertens 2010;28:1738–44.
13. Baber U, Howard VJ, Halperin JL, et al. Asso-
ciation of chronic kidney disease with atrial fibril-
lation among adults in the United States: REasons
for Geographic and Racial Differences in Stroke
(REGARDS) Study. Circ Arrhythm Electrophysiol
2011;4:26–32.
14. McManus DD, Corteville DC, Shlipak MG, et al.
Relation of kidney function and albuminuria with
atrial fibrillation (from the Heart and Soul Study).
Am J Cardiol 2009;104:1551–5.
15. Liao JN, Chao TF, Liu CJ, et al. Incidence and
risk factors for new-onset atrial fibrillation among
patients with end-stage renal disease undergoing
renal replacement therapy. Kidney Int 2015;87:
1209–15.
16. Bansal N, Fan D, Hsu CY, et al. Incident atrial
fibrillation and risk of end-stage renal disease in
adults with chronic kidney disease. Circulation
2013;127:569–74.
17. Bansal N, Hsu CY, Go AS. Intersection of car-
diovascular disease and kidney disease: atrial
fibrillation. Curr Opin Nephrol Hypertens 2014;23:
275–82.
18. Guo Y, Wang H, Zhao X, et al. Sequential
changes in renal function and the risk of stroke
and death in patients with atrial fibrillation. Int J
Cardiol 2013;168:4678–84.
19. Watanabe H, Watanabe T, Sasaki S, et al. Close
bidirectional relationship between chronic kidney
disease and atrial fibrillation: the Niigata preven-
tive medicine study. Am Heart J 2009;158:
629–36.
20. Zimmerman D, Sood MM, Rigatto C, et al.
Systematic review and meta-analysis of incidence,
prevalence and outcomes of atrial fibrillation in
patients on dialysis. Nephrol Dial Transplant 2012;
27:3816–22.
21. Nelson SE, Shroff GR, Li S, et al. Impact of
chronic kidney disease on risk of incident atrial
fibrillation and subsequent survival in Medicare
patients. J Am Heart Assoc 2012;1:e002097.
22. Hwang HS, Park MW, Yoon HE, et al. Clinical
significance of chronic kidney disease and atrial
fibrillation on morbidity and mortality in patients
with acute myocardial infarction. Am J Nephrol
2014;40:345–52.
23. Bansal N, Fan D, Hsu CY, et al. Incident atrial
fibrillation and risk of death in adults with chronic
kidney disease. J Am Heart Assoc 2014;3:
e001303.
24. Pisters R, Lane DA, Nieuwlaat R, et al. A novel
user-friendly score (HAS-BLED) to assess 1-year
risk of major bleeding in patients with atrial
fibrillation: the Euro Heart Survey. Chest 2010;
138:1093–100.
25. Lip GY, Nieuwlaat R, Pisters R, et al. Refining
clinical risk stratification for predicting stroke and
thromboembolism in atrial fibrillation using a
novel risk factor-based approach: the Euro Heart
Survey on Atrial Fibrillation. Chest 2010;137:
263–72.
26. Nielsen PB, Lane DA, Rasmussen LH, et al.
Renal function and non-vitamin K oral anticoagu-
lants in comparison with warfarin on safety andefficacy outcomes in atrial fibrillation patients: a
systemic review and meta-regression analysis. Clin
Res Cardiol 2015;104:418–29.
27. Marinigh R, Lane DA, Lip GY. Severe renal
impairment and stroke prevention in atrial fibril-
lation: implications for thromboprophylaxis and
bleeding risk. J Am Coll Cardiol 2011;57:1339–48.
28. Watson T, Shantsila E, Lip GY. Mechanisms of
thrombogenesis in atrial fibrillation: Virchow’s
triad revisited. Lancet 2009;373:155–66.
29. Maccallum PK, Mathur R, Hull SA, et al. Pa-
tient safety and estimation of renal function in
patients prescribed new oral anticoagulants for
stroke prevention in atrial fibrillation: a cross-
sectional study. BMJ Open 2013;3:e003343.
30. Yagishita A, Takahashi Y, Takahashi A, et al.
Relationship between transesophageal echocar-
diographic features and glomerular filtration rate
in patients with persistent atrial fibrillation. Heart
Rhythm 2010;7:S387.
31. Providência R, Fernandes A, Paiva L, et al.
Decreased glomerular filtration rate and markers
of left atrial stasis in patients with nonvalvular
atrial fibrillation. Cardiology 2013;124:3–10.
32. Blacher J, Guerin AP, Pannier B, et al. Impact
of aortic stiffness on survival in end-stage renal
disease. Circulation 1999;99:2434–9.
33. Bolton CH, Downs LG, Victory JG, et al.
Endothelial dysfunction in chronic renal failure:
roles of lipoprotein oxidation and pro-
inflammatory cytokines. Nephrol Dial Transplant
2001;16:1189–97.
34. Yildiz A, Oflaz H, Pusuroglu H, et al.
Left ventricular hypertrophy and endothelial
dysfunction in chronic hemodialysis patients. Am J
Kidney Dis 2003;41:616–23.
35. Wang MC, Tsai WC, Chen JY, et al. Stepwise
increase in arterial stiffness corresponding with
the stages of chronic kidney disease. Am J Kidney
Dis 2005;45:494–501.
36. Carrero JJ, Kyriazis J, Sonmez A, et al. Pro-
lactin levels, endothelial dysfunction, and the risk
of cardiovascular events and mortality in patients
with CKD. Clin J Am Soc Nephrol 2012;7:207–15.
37. Heintz B, Schmidt P, Maurin N, et al.
Endothelin-1 potentiates ADP-induced platelet
aggregation in chronic renal failure. Ren Fail 1994;
16:481–9.
38. Recio-Mayoral A, Banerjee D, Streather C,
et al. Endothelial dysfunction, inflammation and
atherosclerosis in chronic kidney disease—a cross-
sectional study of predialysis, dialysis and kidney-
transplantation patients. Atherosclerosis 2011;
216:446–51.
39. Shoji T, Maekawa K, Emoto M, et al. Arterial
stiffness predicts cardiovascular death indepen-
dent of arterial thickness in a cohort of hemodi-
alysis patients. Atherosclerosis 2010;210:145–9.
40. Nishizawa Y, Shoji T, Maekawa K, et al. Intima-
media thickness of carotid artery predicts cardio-
vascular mortality in hemodialysis patients. Am J
Kidney Dis 2003;41:S76–9.
41. Shlipak MG, Fried LF, Crump C, et al. Eleva-
tions of inflammatory and procoagulant bio-
markers in elderly persons with renal insufficiency.
Circulation 2003;107:87–92.42. Pecoits-Filho R, Heimbürger O, Bárány P, et al.
Associations between circulating inflammatory
markers and residual renal function in CRF pa-
tients. Am J Kidney Dis 2003;41:1212–8.
43. Keller C, Katz R, Cushman M, et al. Association
of kidney function with inflammatory and pro-
coagulant markers in a diverse cohort: a cross-
sectional analysis from the Multi-Ethnic Study of
Atherosclerosis (MESA). BMC Nephrol 2008;9:9.
44. Landray MJ, Wheeler DC, Lip GY, et al.
Inflammation, endothelial dysfunction, and
platelet activation in patients with chronic kidney
disease: the chronic renal impairment in Birming-
ham (CRIB) study. Am J Kidney Dis 2004;43:
244–53.
45. Tanaka H, Sonoda M, Kashima K, et al. Impact
of decreased renal function on coagulation and
fibrinolysis in patients with non-valvular atrial
fibrillation. Circ J 2009;73:846–50.
46. Mercier E, Branger B, Vecina F, et al. Tissue
factor coagulation pathway and blood cells acti-
vation state in renal insufficiency. Hematol J 2001;
2:18–25.
47. Adams MJ, Irish AB, Watts GF, et al. Hyper-
coagulability in chronic kidney disease is associ-
ated with coagulation activation but not
endothelial function. Thromb Res 2008;123:
374–80.
48. Costa E, Rocha S, Rocha-Pereira P, et al.
Cross-talk between inflammation, coagulation/
fibrinolysis and vascular access in hemodialysis
patients. J Vasc Access 2008;9:248–53.
49. Shen L, Lu G, Dong N, et al. Von Willebrand
factor, ADAMTS13 activity, TNF-a and their re-
lationships in patients with chronic kidney disease.
Exp Ther Med 2012;3:530–4.
50. Yagmur E, Frank RD, Neulen J, et al. Platelet
hyperaggregability is highly prevalent in patients
with chronic kidney disease: an underestimated
risk indicator of thromboembolic events. Clin Appl
Thrombos Hemost 2015;21:132–8.
51. Healey JS, Morillo CA, Connolly SJ. Role of the
renin-angiotensin-aldosterone system in atrial
fibrillation and cardiac remodeling. Curr Opin
Cardiol 2005;20:31–7.
52. Gusbeth-Tatomir P, Covic A. Causes and con-
sequences of increased arterial stiffness in chronic
kidney disease patients. Kidney Blood Press Res
2007;30:97–107.
53. Chue CD, Townend JN, Steeds RP, et al.
Arterial stiffness in chronic kidney disease: causes
and consequences. Heart 2010;96:817–23.
54. Fadem SZ, Moe SM. Management of chronic
kidney disease mineral-bone disorder. Adv Chronic
Kidney Dis 2007;14:44–53.
55. Go AS, Fang MC, Udaltsova N, et al., ATRIA
Study Investigators. Impact of proteinuria and
glomerular filtration rate on risk of thromboem-
bolism in atrial fibrillation: the Anticoagulation
and Risk Factors in Atrial Fibrillation (ATRIA)
study. Circulation 2009;119:1363–9.
56. Olesen JB, Lip GY, Kamper AL, et al. Stroke
and bleeding in atrial fibrillation with chronic
kidney disease. N Engl J Med 2012;367:625–35.
57. Bonde AN, Lip GY, Kamper AL, et al. Net
clinical benefit of antithrombotic therapy in
J A C C V O L . 6 8 , N O . 1 3 , 2 0 1 6 Lau et al.
S E P T E M B E R 2 7 , 2 0 1 6 : 1 4 5 2 – 6 4 AF, CKD, and Thromboembolic Risk
1463patients with atrial fibrillation and chronic kidney
disease: a nationwide observational cohort study.
J Am Coll Cardiol 2014;64:2471–82.
58. Friberg L, Benson L, Lip GY. Balancing stroke
and bleeding risks in patients with atrial fibrillation
and renal failure: the Swedish Atrial Fibrillation
Cohort study. Eur Heart J 2015;36:297–306.
59. Akazawa T, Nishihara H, Iwata H, et al. Pre-
operative plasma brain natriuretic peptide level is
an independent predictor of postoperative atrial
fibrillation following off-pump coronary artery
bypass surgery. J Anesth 2008;22:347–53.
60. Chinda J, Nakagawa N, Kabara M, et al. Impact
of decreased estimated glomerular filtration rate
on Japanese acute stroke and its subtype. Intern
Med 2012;51:1661–6.
61. Roldán V, Marin F, Fernández H, et al. Renal
impairment in a “real-life” cohort of anti-
coagulated patients with atrial fibrillation (impli-
cations for thromboembolism and bleeding). Am J
Cardiol 2013;111:1159–64.
62. Kumai Y, Kamouchi M, Hata J, et al., FSR In-
vestigators. Proteinuria and clinical outcomes af-
ter ischemic stroke. Neurology 2012;78:1909–15.
63. Yahalom G, Schwartz R, Schwammenthal Y,
et al. Chronic kidney disease and clinical outcome
in patients with acute stroke. Stroke 2009;40:
1296–303.
64. Shimizu Y, Maeda K, Imano H, et al. Chronic
kidney disease and drinking status in relation to
risks of stroke and its subtypes: the Circulatory
Risk in Communities Study (CIRCS). Stroke 2011;
42:2531–7.
65. Bos MJ, Koudstaal PJ, Hofman A, et al.
Decreased glomerular filtration rate is a risk factor
for hemorrhagic but not for ischemic stroke: the
Rotterdam study. Stroke 2007;38:3127–32.
66. Iseki K, Kinjo K, Kimura Y, et al. Evidence for
high risk of cerebral hemorrhage in chronic dialysis
patients. Kidney Int 1993;44:1086–90.
67. Ovbiagele B, Wing JJ, Menon RS, et al. Asso-
ciation of chronic kidney disease with cerebral
microbleeds in patients with primary intracerebral
hemorrhage. Stroke 2013;44:2409–13.
68. Sood P, Kumar G, Nanchal R, et al. Chronic
kidney disease and end-stage renal disease predict
higher risk of mortality in patients with primary
upper gastrointestinal bleeding. Am J Nephrol
2012;35:216–24.
69. Kuo CC, Kuo HW, Lee IM, et al. The risk of
upper gastrointestinal bleeding in patients treated
with hemodialysis: a population-based cohort
study. BMC Nephrol 2013;14:15.
70. Luo JC, Leu HB, Hou MC, et al. Nonpeptic ul-
cer, nonvariceal gastrointestinal bleeding in he-
modialysis patients. Am J Med 2013;126:264.
e25–32.
71. Huang KW, Leu HB, Luo JC, et al. Different
peptic ulcer bleeding risk in chronic kidney disease
and end-stage renal disease patients receiving
different dialysis. Dig Dis Sci 2014;59:807–13.
72. Ng KP, Edwards NC, Lip GY, et al. Atrial
fibrillation in CKD: balancing the risks and benefits
of anticoagulation. Am J Kidney Dis 2013;62:
615–32.73. Reinecke H, Brand E, Mesters R, et al. Di-
lemmas in the management of atrial fibrillation in
chronic kidney disease. J Am Soc Nephrol 2009;
20:705–11.
74. Vanhoutte PM, Feletou M, Taddei S.
Endothelium-dependent contractions in hyper-
tension. Br J Pharmacol 2005;144:449–58.
75. Authors/Task Force Members, Camm AJ,
Lip GYH, et al. 2012 focused update of the ESC
Guidelines for the management of atrial fibrilla-
tion. Eur Heart J 2012;33:2719–47.
76. Olesen JB, Lip GY, Hansen ML, et al. Validation
of risk stratification schemes for predicting stroke
and thromboembolism in patients with atrial
fibrillation: nationwide cohort study. BMJ 2011;
342:d124.
77. Piccini JP, Stevens SR, Chang Y, et al., ROCKET
AF Steering Committee and Investigators. Renal
dysfunction as a predictor of stroke and systemic
embolism in patients with nonvalvular atrial
fibrillation: validation of the R2CHADS2 index in
the ROCKET AF (Rivaroxaban Once-daily, oral,
direct factor Xa inhibition Compared with vitamin
K antagonism for prevention of stroke and Em-
bolism Trial in Atrial Fibrillation) and ATRIA
(AnTicoagulation and Risk factors In Atrial fibril-
lation) study cohorts. Circulation 2013;127:224–32.
78. Bautista J, Bella A, Chaudhari A, et al.
Advanced chronic kidney disease in non-valvular
atrial fibrillation: extending the utility of
R2CHADS2 to patients with advanced renal failure.
Clin Kidney J 2015;8:226–31.
79. Kornej J, Hindricks G, Kosiuk J, et al.
Renal dysfunction, stroke risk scores (CHADS2,
CHA2DS2-VASc, and R2CHADS2), and the risk of
thromboembolic events after catheter ablation of
atrial fibrillation: the Leipzig Heart Center AF
Ablation Registry. Circ Arrhythm Electrophysiol
2013;6:868–74.
80. Abumuaileq RR, Abu-Assi E, López-López A,
et al. Comparison between CHA2DS2-VASc and
the new R2CHADS2 and ATRIA scores at predicting
thromboembolic event in non-anticoagulated and
anticoagulated patients with non-valvular atrial
fibrillation. BMC Cardiovasc Disord 2015;15:156.
81. Chao TF, Lin YJ, Chang SL, et al. R2CHADS2
score and thromboembolic events after catheter
ablation of atrial fibrillation in comparison with
the CHA2DS2-VASc score. Can J Cardiol 2014;30:
405–12.
82. Roldán V, Marín F, Manzano-Fernandez S,
et al. Does chronic kidney disease improve the
predictive value of the CHADS2 and CHA2DS2-
VASc stroke stratification risk scores for atrial
fibrillation? Thromb Haemost 2013;109:956–60.
83. Banerjee A, Fauchier L, Vourc’h P, et al. Renal
impairment and ischemic stroke risk assessment in
patients with atrial fibrillation: the Loire Valley
atrial fibrillation project. J Am Coll Cardiol 2013;
61:2079–87.
84. Sengupta N, Feuerstein JD, Patwardhan VR,
et al. The risks of thromboembolism vs. recurrent
gastrointestinal bleeding after interruption of
systemic anticoagulation in hospitalized inpatients
with gastrointestinal bleeding: a prospective
study. Am J Gastroenterol 2015;110:328–35.85. Staerk L, Lip GY, Olesen JB, et al. Stroke and
recurrent haemorrhage associated with antith-
rombotic treatment after gastrointestinal bleeding
in patients with atrial fibrillation: nationwide
cohort study. BMJ 2015;351:h5876.
86. Khalid F, Qureshi W, Qureshi S, et al. Impact of
restarting warfarin therapy in renal disease anti-
coagulated patients with gastrointestinal hemor-
rhage. Ren Fail 2013;35:1228–35.
87. Boriani G, Savelieva I, Dan GA, et al. Chronic
kidney disease in patients with cardiac rhythm
disturbances or implantable electrical devices:
clinical significance and implications for decision
making-a position paper of the European Heart
Rhythm Association endorsed by the Heart
Rhythm Society and the Asia Pacific Heart Rhythm
Society. Europace 2015;17:1169–96.
88. Lane DA, Aguinaga L, Blömstrom-Lundqvist C,
et al. Cardiac tachyarrhythmias and patient values
and preferences for their management: the Euro-
pean Heart Rhythm Association (EHRA) consensus
document endorsed by the Heart Rhythm Society
(HRS), Asia Pacific Heart Rhythm Society (APHRS),
and Sociedad Latinoamericana de Estimulación
Cardiaca y Electrofisiologia (SOLEACE). Europace
2015;17:1747–69.
89. Lane DA, Lip GYH. Patient’s values and pref-
erences for stroke prevention in atrial fibrillation:
Balancing stroke and bleeding risk with oral anti-
coagulation. Thromb Haemost 2014;111:381–3.
90. Potpara TS, Lenarczyk R, Larsen TB, et al.
Management of atrial fibrillation in patients with
chronic kidney disease in Europe. Results of the
European Heart Rhythm Association Survey.
Europace 2015;17:1862–7.
91. Li M, Liu T, Luo D, et al. Systematic review and
meta-analysis of chronic kidney disease as pre-
dictor of atrial fibrillation recurrence following
catheter ablation. Cardiol J 2014;21:89–95.
92. Hayashi M, Kaneko S, Shimano M, et al.
Efficacy and safety of radiofrequency catheter
ablation for atrial fibrillation in chronic hemodial-
ysis patients. Nephrol Dial Transplant 2014;29:
160–7.
93. Kornej J, Hindricks G, Banerjee A, et al.
Changes in renal function after catheter ablation
of atrial fibrillation are associated with CHADS2
and CHA2DS2-VASc scores and arrhythmia re-
currences. Heart 2015;101:126–31.
94. Williams ES, Thompson VP, Chiswell KE, et al.
Rate versus rhythm control and outcomes in pa-
tients with atrial fibrillation and chronic kidney
disease: data from the GUSTO-III Trial. Cardiol J
2013;20:439–46.
95. Abbott KC, Trespalacios FC, Taylor AJ, et al.
Atrial fibrillation in chronic dialysis patients in the
United States: risk factors for hospitalization and
mortality. BMC Nephrol 2003;4:1.
96. Olesen JB, Lip GY, Lindhardsen J, et al. Risks
of thromboembolism and bleeding with throm-
boprophylaxis in patients with atrial fibrillation: A
net clinical benefit analysis using a ’real world’
nationwide cohort study. Thromb Haemost 2011;
106:739–49.
97. Genovesi S, Rossi E, Gallieni M, et al.
Warfarin use, mortality, bleeding and stroke in
Lau et al. J A C C V O L . 6 8 , N O . 1 3 , 2 0 1 6
AF, CKD, and Thromboembolic Risk S E P T E M B E R 2 7 , 2 0 1 6 : 1 4 5 2 – 6 4
1464haemodialysis patients with atrial fibrillation.
Nephrol Dial Transplant 2015;30:491–8.
98. Chan PH, Huang D, Yip PS, et al. Ischaemic
stroke in patients with atrial fibrillation with
chronic kidney disease undergoing peritoneal
dialysis. Europace 2016;18:665–71.
99. Findlay MD, Thomson PC, Fulton RL, et al.
Risk factors of ischemic stroke and subsequent
outcome in patients receiving hemodialysis. Stroke
2015;46:2477–81.
100. Knoll F, Sturm G, Lamina C, et al. Coumarins
and survival in incident dialysis patients. Nephrol
Dial Transplant 2012;27:332–7.
101. Shen JI, Montez-Rath ME, Lenihan CR, et al.
Outcomes after warfarin initiation in a cohort of
hemodialysis patients with newly diagnosed atrial
fibrillation. Am J Kidney Dis 2015;66:677–88.
102. Chen JJ, Lin LY, Yang YH, et al. Anti-platelet
or anti-coagulant agent for the prevention of
ischemic stroke in patients with end-stage renal
disease and atrial fibrillation—a nation-wide data-
base analyses. Int J Cardiol 2014;177:1008–11.
103. Wiesholzer M, Harm F, Tomasec G, et al.
Incidence of stroke among chronic hemodialysis
patients with nonrheumatic atrial fibrillation. Am J
Nephrol 2001;21:35–9.
104. Chan KE, Lazarus JM, Thadhani R, et al.
Warfarin use associates with increased risk for
stroke in hemodialysis patients with atrial fibril-
lation. J Am Soc Nephrol 2009;20:2223–33.
105. Wizemann V, Tong L, Satayathum S, et al.
Atrial fibrillation in hemodialysis patients: clinical
features and associations with anticoagulant
therapy. Kidney Int 2010;77:1098–106.
106. Phelan PJ, O’Kelly P, Holian J, et al. Warfarin
use in hemodialysis patients: what is the risk? Clin
Nephrol 2011;75:204–11.
107. Winkelmayer WC, Liu J, Setoguchi S, et al.
Effectiveness and safety of warfarin initiation in
older hemodialysis patients with incident atrial
fibrillation. Clin J Am Soc Nephrol 2011;6:2662–8.
108. Sood MM, Larkina M, Thumma JR, et al.
Major bleeding events and risk stratification of
antithrombotic agents in hemodialysis: results
from the DOPPS. Kidney Int 2013;84:600–8.
109. Shah M, Avgil Tsadok M, Jackevicius CA,
et al. Warfarin use and the risk for stroke and
bleeding in patients with atrial fibrillation under-
going dialysis. Circulation 2014;129:1196–203.
110. Wakasugi M, Kazama JJ, Tokumoto A, et al.
Association between warfarin use and incidence of
ischemic stroke in Japanese hemodialysis patients
with chronic sustained atrial fibrillation: a prospec-
tive cohort study. Clin Exp Nephrol 2014;18:662–9.
111. Lai HM, Aronow WS, Kalen P, et al. Incidence
of thromboembolic stroke and of major bleeding
in patients with atrial fibrillation and chronic kid-
ney disease treated with and without warfarin. Int
J Nephrol Renovasc Dis 2009;2:33–7.
112. Hart RG, Pearce LA, Asinger RW, et al.
Warfarin in atrial fibrillation patients with moder-
ate chronic kidney disease. Clin J Am Soc Nephrol
2011;6:2599–604.
113. Providência R, Marijon E, Boveda S, et al.
Meta-analysis of the influence of chronic kidneydisease on the risk of thromboembolism among
patients with nonvalvular atrial fibrillation. Am J
Cardiol 2014;114:646–53.
114. Proietti M, Lane DA, Lip GYH. Chronic kidney
disease, time in therapeutic range and adverse
clinical outcomes in anticoagulated patients with
non–valvular atrial fibrillation: observations from
the SPORTIF Trials. EBioMedicine 2016;8:309–16.
115. Koos R, Krueger T, Westenfeld R, et al. Rela-
tion of circulating Matrix Gla-Protein and anti-
coagulation status in patients with aortic valve
calcification. Thromb Haemost 2009;101:706–13.
116. Luo G, Ducy P, McKee MD, et al. Spontaneous
calcification of arteries and cartilage in mice
lacking matrix GLA protein. Nature 1997;386:
78–81.
117. Galloway PA, El-Damanawi R, Bardsley V,
et al. Vitamin K antagonists predispose to calci-
phylaxis in patients with end-stage renal disease.
Nephron 2015;129:197–201.
118. Hayashi M, Takamatsu I, Kanno Y, et al.,
Japanese Calciphylaxis StudyGroup. A case-control
study of calciphylaxis in Japanese end-stage renal
disease patients. Nephrol Dial Transplant 2012;27:
1580–4.
119. Connolly SJ, Eikelboom J, Joyner C, et al.,
AVERROES Steering Committee and Investigators.
Apixaban in patients with atrial fibrillation. N Engl
J Med 2011;364:806–17.
120. Connolly SJ, Ezekowitz MD, Yusuf S, et al.,
RE-LY Steering Committee and Investigators.
Dabigatran versus warfarin in patients with atrial
fibrillation. N Engl J Med 2009;361:1139–51.
121. Granger CB, Alexander JH, McMurray JJV,
et al., ARISTOTLE Committees and Investigators.
Apixaban versus warfarin in patients with atrial
fibrillation. N Engl J Med 2011;365:981–92.
122. Patel MR, Mahaffey KW, Garg J, et al.,
ROCKET AF Investigators. Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation. N Engl J
Med 2011;365:883–91.
123. Giugliano RP, Ruff CT, Braunwald E, et al.,
ENGAGE AF-TIMI 48 Investigators. Edoxaban
versus warfarin in patients with atrial fibrillation.
N Engl J Med 2013;369:2093–104.
124. Hijazi Z, Hohnloser SH, Oldgren J, et al. Ef-
ficacy and safety of dabigatran compared with
warfarin in relation to baseline renal function in
patients with atrial fibrillation: a RE-LY (Random-
ized Evaluation of Long-term Anticoagulation
Therapy) trial analysis. Circulation 2014;129:
961–70.
125. Fox KA, Piccini JP, Wojdyla D, et al. Preven-
tion of stroke and systemic embolism with rivar-
oxaban compared with warfarin in patients with
non-valvular atrial fibrillation and moderate renal
impairment. Eur Heart J 2011;32:2387–94.
126. Hohnloser SH, Hijazi Z, Thomas L, et al. Effi-
cacy of apixaban when compared with warfarin in
relation to renal function in patients with atrial
fibrillation: insights from the ARISTOTLE trial. Eur
Heart J 2012;33:2821–30.
127. Proietti M, Lip GY. Edoxaban in venous
thromboembolism and stroke prevention: an
appraisal. Vasc Health Risk Manag 2016;12:45–51.128. Huisman MV, Lip GY, Diener HC, et al. Dabi-
gatran etexilate for stroke prevention in patients
with atrial fibrillation: resolving uncertainties in
routine practice. Thromb Haemost 2012;107:
838–47.
129. Turpie AG. Rivaroxaban as an oral anticoag-
ulant for stroke prevention in atrial fibrillation.
Ther Clin Risk Manag 2014;10:197–205.
130. Heidbuchel H, Verhamme P, Alings M, et al.
European Heart Rhythm Association Practical
Guide on the use of new oral anticoagulants in
patients with non-valvular atrial fibrillation.
Europace 2013;15:625–51.
131. Manzano-Fernández S, Andreu-Cayuelas JM,
Marín F, et al. Comparison of estimated
glomerular filtration rate equations for dosing
new oral anticoagulants in patients with atrial
fibrillation. Rev Esp Cardiol (Engl Ed) 2015;68:
497–504.
132. Eliquis (apixaban) [tablet prescribing infor-
mation]. Princeton, NJ: Bristol-Meyers Squibb,
2015.
133. Savaysa (edoxoban) [prescribing informa-
tion]. Parsippany, NJ: Daiichi Sankyo, Inc., 2015.
134. De Caterina R, Husted S, Wallentin L, et al.
Vitamin K antagonists in heart disease: current
status and perspectives (section III). Position pa-
per of the ESC Working Group on Thrombosis—
Task Force on Anticoagulants in Heart Disease.
Thromb Haemost 2013;110:1087–107.
135. Andreu-Cayuelas JM, Pastor-Pérez FJ,
Puche CM, et al. Impact of variations in kidney
function on nonvitamin K oral anticoagulant
dosing in patients with atrial fibrillation and recent
acute heart failure. Rev Esp Cardiol (Engl Ed)
2016;69:134–40.
136. Miyamoto K, Aiba T, Arihiro S, et al. Impact of
renal function deterioration on adverse events
during anticoagulation therapy using non-vitamin
K antagonist oral anticoagulants in patients
with atrial fibrillation. Heart Vessels 2016;31:
1327–36.
137. Hrafnkelsdóttir T, Ottosson P, Gudnason T,
et al. Impaired endothelial release of tissue-type
plasminogen activator in patients with chronic
kidney disease and hypertension. Hypertension
2004;44:300–4.
138. Friberg L, Rosenqvist M, Lip GY. Evalua-
tion of risk stratification schemes for ischaemic
stroke and bleeding in 182,678 patients
with atrial fibrillation: the Swedish atrial
fibrillation cohort study. Eur Heart J 2012;33:
1500–10.
139. Chao TF, Liu CJ, Wang KL, et al. Incidence
and prediction of ischemic stroke among atrial
fibrillation patients with end-stage renal dis-
ease requiring dialysis. Heart Rhythm 2014;11:
1752–9.
140. Banerjee A, Fauchier L, Vourc’h P, et al.
A prospective study of estimated glomerular
filtration rate and outcomes in patients with atrial
fibrillation: the Loire Valley Atrial Fibrillation
Project. Chest 2014;145:1370–82.
KEY WORDS anticoagulation, bleeding
risk, stroke prevention
